Scientists have long attempted to create vaccines that coax the immune system into recognizing the fusion (F) proteins present on the surfaces of RSV, hMPV and related viruses. These proteins play ...

Scientists have long attempted to create vaccines that coax the immune system into recognizing the fusion (F) proteins present on the surfaces of RSV, hMPV and related viruses. These proteins play ...

First, they must enter the host cells, which RSV does using its fusion (F) protein. Vaccines induce antibodies that bind to pathogens. Neutralizing antibodies bind to crucial sites, such as part ...

Subscribe for FREE Scientists have long attempted to create vaccines that coax the immune system into recognizing the fusion (F) proteins present on the surfaces of RSV, hMPV and related viruses.

Despite 50 years of research, there are currently no RSV vaccines approved or in Phase III trials for any of the target populations. High levels of neutralizing antibodies to RSV F protein have ...

Johns Hopkins Medicine researchers have shown that people 60 years or older with weakened immunity -; primarily organ transplant recipients who take immunosuppressive medications to reduce the risk of ...

The acquisition focuses on sisunotavir, an RSV fusion inhibitor that UK-based ReViral ... including a follow-up RSV candidate targeting the viral N protein that is in phase 1 testing.

Discover how RSV vaccines perform in seniors with compromised immunity, especially organ transplant recipients.